FDA
-
-
-
-
-
-
-
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
-
-
-
-
-
-
-
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
-
-
-
-
-
322,950 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

